SSA
CASI

Schonfeld Strategic Advisors’s CASI Pharmaceuticals CASI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,960
Closed -$24K – 2173
2021
Q3 		$24K Sell
1,960
-100
-5% -$1.35K ﹤0.01% 2042
2021
Q2 		$32K Buy
+2,060
New +$34.7K ﹤0.01% 1882

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Schonfeld Strategic Advisors's CASI Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of CASI Pharmaceuticals (CASI) in Q4 2021, closing a stake of 1,960 shares — an estimated $24K sold.

Schonfeld Strategic Advisors first reported a position in CASI in Q2 2021 and held it in 2 quarters. The position peaked at $32K in Q2 2021. 51 funds tracked by Wall St. Rank hold CASI as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining CASI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,960 CASI Pharmaceuticals shares in Q4 2021, an estimated $24K.
  • Schonfeld Strategic Advisors first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's CASI Pharmaceuticals position peaked at $32K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.